H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
TD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $5
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Chimerix Analyst Ratings
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $5
Chimerix's Positive Phase 3 Trial Progress and Strong Financial Position Justify 'Buy' Rating
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Capital One Financial Maintains Chimerix(CMRX.US) With Buy Rating, Cuts Target Price to $6
Chimerix Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
No Data